Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
KPTI•Outlook and liquidity
The company reaffirmed its 2026 total revenue guidance of $130 million to $150 million.
Karyopharm expects 2026 U.S. XPOVIO net product revenue of $115 million to $130 million.
The company said existing liquidity is expected to fund operations into September 2026.
Drivers behind the quarter
- Steady XPOVIO demand - The company said U.S. XPOVIO net product revenue was stable in Q2 2026 despite increased competition in multiple myeloma.
- Royalty revenue growth - Karyopharm said expanded global patient access for selinexor led to higher royalty revenue from international partners.
- License revenue decline - The company attributed lower license and other revenue to the expiration of Menarini's annual R&D obligation.
Quarterly results and analyst view
| Metric | Actual |
|---|---|
| Q2 Product Revenue | $30.78 million |
| Q2 Net Loss | $67.02 million |
| Q2 Operating Expenses |
Related News
Babcock & Wilcox publishes investor presentation outlining AI data center power strategy, $14 billion pipeline
BW•
American Express Expands Virtual Card Capabilities To Help Businesses Utilize Fast-Growing Commercial Payment Method
AXP•
